BioSpace News Archive

The FDA has granted emergency use authorization to InflaRx’s vilobelimab, now to be marketed as Gohibic, for hospitalized adult patients with COVID-19, the German biotech announced Tuesday.

Relocating for work can be exciting, but it can also be costly. Read on to find out how to negotiate a relocation package to simplify your move.

AstraZeneca’s Imfinzi and Lynparza met primary endpoint markers in the Phase III DUO-O trial in advanced high-grade epithelial ovarian cancer, according to data released Wednesday.

Proxygen added Merck to its partner roster on Wednesday, garnering an undisclosed upfront payment plus a potential $2.55 billion in milestones.

Corcept Therapeutics Incorporated announced the final results of its previously announced tender offer to purchase up to 7,500,000 shares of its common stock, par value $0.001 per share, at a price not greater than $22.00 nor less than $19.25 per share, in cash, less any applicable withholding taxes and without interest, which expired one minute after 11:59 p.m., New York City time, on March 31, 2023.

Fusion Pharmaceuticals Inc. announced that the compensation committee of the Company’s Board of Directors granted stock option awards to purchase an aggregate of 258,000 shares of its common stock to four employees outside Fusion’s 2020 Stock Option and Incentive Plan.

Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today reported financial results for its second quarter of fiscal 2023, ended February 28, 2023.

Nox Medical has secured a new patent to measure breathing movements for determining endophenotypes of sleep-disordered breathing using Nox RIP technology.

Nutex Health Inc. today announced the departure of Matthew Young, M.D. from the Company’s Board of Directors at the end of his one year term commitment and the election of Danniel Stites, M.D. to the Board.

Scilex Holding Company, a subsidiary of Sorrento Therapeutics, Inc., announced that the Company’s 2023 Annual Meeting of Stockholders that was scheduled to be held at 9:00 a.m. on Thursday, April 6, 2023, has been postponed to April 17, 2023 at 9:00 a.m.